

<p>主講人</p>	<p>歐建志 (Chien-Chih Ou) 博士</p>	
<p>講題 (Topic)</p>	<p><b>Cancer immune therapy—from basic biology to clinical trial</b></p>	
<p>演講摘要 (Abstract)</p>	<p>Cancer cells employ several mechanisms to evade anti-cancer drug therapy. Of particular interest is cancer cells can develop various strategies to escape patients' immune surveillance, thus, creating frontier immunotherapies become the attractive idea for anti-cancer therapy. Immune Checkpoint Molecules, which can bind inhibitory signals between cancer cells and immune cells to activate host immunity, demonstrated unobserved and superior to conventional therapy results in clinical trials. Anti-PD-1/PD-L1 axis and Anti-CTLA-4 antibodies are two typical classes of immune checkpoint inhibitors approved by regulatory authorities which showed ~20% of response rate in melanoma, NSCLC, RCC and urothelial cancers. Cancer therapeutic vaccines are administrated to cancer patients and designed to eradicate cancer cells through strengthening patient's own immune responses. Although several therapeutic vaccination strategies are under development or being evaluated in clinical trials, only Sipuleucel-T was approved by the US FDA in 2010 for the treatment of asymptomatic metastatic castrate-resistant prostate cancer. T cell adoptive transfer therapy is new technology to engineer expression of chimeric antigen receptors (CAR) or T cell receptor on the surface of T cells enables the redirection of T-cell to specific oncotargets. Early-phase clinical trials are currently assessing safety and efficacy of CAR-T cells in cancer patients but only hematologic malignancies hold the therapeutic potentials. Oncolytic viruses represent a new class of immune oncology therapy that promotes anti-tumor responses through a dual mechanism of action that is dependent on selective tumor cell killing and the induction of systemic anti-tumor immunity. A variety of native and genetically modified viruses have been developed as oncolytic agents, and the approval of the first oncolytic virus by regulatory authority is anticipated in the near future.</p>	

<p>主講人 簡介 (Biography)</p>	<p><b>EDUCATION:</b>  Jan 2008 Ph.D., Graduate Institute of Medical Sciences,  National Defense Medical Center, Taipei, Taiwan  Aug 2002 M.S., Graduate Institute of Pharmacology,  National Defense Medical Center, Taipei, Taiwan  Aug 1995 B.S., Department of Pharmacy, Kaohsiung Medical University,  Kaohsiung, Taiwan</p>
	<p><b>EXPERIENCE:</b>  Oct 2015 - Present Associate Director, Medical and Clinical Program and  Development, OBI Pharma  Jan 2011 - Sep 2015 Project Manager, Project Head/Director,  SynCore and Sinphar Group in Taiwan  Jan 2008 - Dec 2010 Postdoctoral Study in Tri-Services General Hospital,  National Defense Medical Center, Taipei, Taiwan  Jul 2009 - Jun 2011 Adjunct assistant professor, National Defense Medical Center,  Taipei, Taiwan  Aug 1997 - Aug 2000 Sales Representative, Roche Pharmaceutical Company  Oct 1995 - Jun 1997 Military Pharmacist, Taiwan</p>